Adiponectin: Key player in the adipose tissue-liver crosstalk

Current Medicinal Chemistry

Volumn 19, Issue 32, 2012, Pages 5467-5473

  Moschen, A R ^a   Wieser, V ^a   Tilg, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adipocytokines; Cytokines; Inflammation; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SHORT HAIRPIN RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE HEPATITIS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIUM CELL; ENZYME INDUCTION; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; LIVER REGENERATION; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIMARY BILIARY CIRRHOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; HUMANS; LIVER; LIVER DISEASES;

EID: 84870452496     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833254     Document Type: Article

References (95)

1. Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270(45), 26746-26749.
2. Tilg, H.; Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat.Rev.Immunol., 2006, 6(10), 772-783.
3. Wolf, A. M.; Wolf, D.; Avila, M. A.; Moschen, A. R.; Berasain, C.; Enrich, B.; Rumpold, H.; Tilg, H. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J.Hepatol., 2006, 44(3), 537-543.
4. Pineiro, R.; Iglesias, M. J.; Gallego, R.; Raghay, K.; Eiras, S.; Rubio, J.; Dieguez, C.; Gualillo, O.; Gonzalez-Juanatey, J. R.; Lago, F. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett., 2005, 579(23), 5163-5169.
5. Delaigle, A. M.; Jonas, J. C.; Bauche, I. B.; Cornu, O.; Brichard, S. M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology, 2004, 145(12), 5589-5597.
6. Unger, R. H.; Scherer, P. E. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol. Metab., 2010, 21(6), 345-352.
7. Sun, K.; Kusminski, C. M.; Scherer, P. E. Adipose tissue remodeling and obesity. J. Clin. Invest., 2011, 121(6), 2094-2101.
8. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N. H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki, T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423(6941), 762-769.
9. Tilg, H.; Moschen, A. R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab, 2008, 19(10), 371-379.
10. Raptis, D. A.; Fischer, M. A.; Graf, R.; Nanz, D.; Weber, A.; Moritz, W.; Tian, Y.; Oberkofler, C. E.; Clavien, P. A. MRI: the new reference standard in quantifying hepatic steatosis? Gut, 2011.
11. Tamimi, T. I.; Elgouhari, H. M.; Alkhouri, N.; Yerian, L. M.; Berk, M. P.; Lopez, R.; Schauer, P. R.; Zein, N. N.; Feldstein, A. E. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J. Hepatol., 2011, 54(6), 1224-1229.
12. Marchesini, G.; Forlani, G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology, 2002, 35(2), 497-499.
13. Lonardo, A.; Bellentani, S.; Ratziu, V.; Loria, P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev. Gastroenterol. Hepatol., 2011, 5(2), 279-289.
14. Gregor, M. F.; Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol., 2011, 29, 415-445.
15. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100(25), 2473-2476.
16. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ouchi, N.; Kihara, S.; Funahashi, T.; Tenner, A. J.; Tomiyama, Y.; Matsuzawa, Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, 96(5), 1723-1732.
17. Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T.; Matsuzawa, Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med., 2002, 8(7), 731-737.
18. Wolf, A. M.; Wolf, D.; Rumpold, H.; Enrich, B.; Tilg, H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun., 2004, 323(2), 630-635.
19. Mandal, P.; Park, P. H.; McMullen, M. R.; Pratt, B. T.; Nagy, L. E. The antiinflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology, 2010, 51(4), 1420-1429.
20. Lin, H.; Yu, C. H.; Jen, C. Y.; Cheng, C. F.; Chou, Y.; Chang, C. C.; Juan, S. H. Adiponectin-mediated heme oxygenase-1 induction protects against ironinduced liver injury via a PPARalpha dependent mechanism. Am. J. Pathol., 2010, 177(4), 1697-1709.
21. Mandal, P.; Roychowdhury, S.; Park, P. H.; Pratt, B. T.; Roger, T.; Nagy, L. E. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. J. Immunol., 2010, 185(8), 4928-4937.
22. Bruun, J. M.; Lihn, A. S.; Verdich, C.; Pedersen, S. B.; Toubro, S.; Astrup, A.; Richelsen, B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab., 2003, 285(3), E527-E533.
23. Moschen, A. R.; Molnar, C.; Geiger, S.; Graziadei, I.; Ebenbichler, C. F.; Weiss, H.; Kaser, S.; Kaser, A.; Tilg, H. Anti-inflammatory effects of excessive Weight loss: potent suppression of adipose interleukin-6 and tumour necrosis factor-alpha expression. Gut, 2010, 59, 1259-1264.
24. Iwaki, M.; Matsuda, M.; Maeda, N.; Funahashi, T.; Matsuzawa, Y.; Makishima, M.; Shimomura, I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003, 52(7), 1655-1663.
25. He, W.; Barak, Y.; Hevener, A.; Olson, P.; Liao, D.; Le, J.; Nelson, M.; Ong, E.; Olefsky, J. M.; Evans, R. M. Adipose-specific peroxisome proliferatoractivated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A, 2003, 100(26), 15712-15717.
26. Hui, J. M.; Hodge, A.; Farrell, G. C.; Kench, J. G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 2004, 40(1), 46-54.
27. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 1999, 257(1), 79-83.
28. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 2000, 20(6), 1595-1599.
29. Lopez-Bermejo, A.; Botas, P.; Funahashi, T.; Delgado, E.; Kihara, S.; Ricart, W.; Fernandez-Real, J. M. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin. Endocrinol. (Oxf), 2004, 60(2), 256-263.
30. Moschen, A. R.; Molnar, C.; Wolf, A. M.; Weiss, H.; Graziadei, I.; Kaser, S.; Ebenbichler, C. F.; Stadlmann, S.; Moser, P. L.; Tilg, H. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J. Hepatol., 2009, 51(4), 765-777.
31. Savvidou, S.; Hytiroglou, P.; Orfanou-Koumerkeridou, H.; Panderis, A.; Frantzoulis, P.; Goulis, J. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J. Clin. Gastroenterol., 2009, 43(8), 765-772.
32. Nazal, L.; Riquelme, A.; Solis, N.; Pizarro, M.; Escalona, A.; Burotto, M.; Mendez, J. I.; Saint-Jean, C.; Concha, M. J.; Giovanni, S.; Awruch, D.; Morales, A.; Baudrand, R.; Carrasco, G.; Dominguez, M. A.; Padilla, O.; Espinoza, M.; Miquel, J. F.; Nervi, F.; Arrese, M. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes. Surg., 2010, 20(10), 1400-1407.
33. Kawamoto, R.; Tabara, Y.; Kohara, K.; Miki, T.; Ohtsuka, N.; Kusunoki, T.; Abe, M. Alcohol drinking status is associated with serum high molecular weight adiponectin in community-dwelling Japanese men. J. Atheroscler. Thromb., 2010, 17(9), 953-962.
34. Polyzos, S. A.; Toulis, K. A.; Goulis, D. G.; Zavos, C.; Kountouras, J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism, 2011, 60(3), 313-326.
35. Bianchi, G.; Bugianesi, E.; Frystyk, J.; Tarnow, L.; Flyvbjerg, A.; Marchesini, G. Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Dig. Liver Dis., 2011, 43(1), 73-77.
36. Engl, J.; Sturm, W.; Sandhofer, A.; Kaser, S.; Tschoner, A.; Tatarczyk, T.; Weiss, H.; Tilg, H.; Patsch, J. R.; Ebenbichler, C. F. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur. J. Clin. Invest., 2008, 38(4), 238-244.
37. Turer, A. T.; Khera, A.; Ayers, C. R.; Turer, C. B.; Grundy, S. M.; Vega, G. L.; Scherer, P. E. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia, 2011, 54(10), 2515-2524.
38. Ayonrinde, O. T.; Olynyk, J. K.; Beilin, L. J.; Mori, T. A.; Pennell, C. E.; de Klerk, N.; Oddy, W. H.; Shipman, P.; Adams, L. A. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology, 2011, 53(3), 800-809.
39. Hirose, H.; Kawai, T.; Yamamoto, Y.; Taniyama, M.; Tomita, M.; Matsubara, K.; Okazaki, Y.; Ishii, T.; Oguma, Y.; Takei, I.; Saruta, T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism., 2002, 51(3), 314-317.
40. Lutchman, G.; Promrat, K.; Kleiner, D. E.; Heller, T.; Ghany, M. G.; Yanovski, J. A.; Liang, T. J.; Hoofnagle, J. H. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol., 2006, 4(8), 1048-1052.
41. Balmer, M. L.; Siegrist, K.; Zimmermann, A.; Dufour, J. F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int., 2009, 29(8), 1184-1188.
42. Sanyal, A. J.; Chalasani, N.; Kowdley, K. V.; McCullough, A.; Diehl, A. M.; Bass, N. M.; Neuschwander-Tetri, B. A.; Lavine, J. E.; Tonascia, J.; Unalp, A.; Van Natta, M.; Clark, J.; Brunt, E. M.; Kleiner, D. E.; Hoofnagle, J. H.; Robuck, P. R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362(18), 1675-1685.
43. Pettinelli, P.; Videla, L. A. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J. Clin. Endocrinol. Metab., 2011, 96(5), 1424-1430.
44. Landrier, J. F.; Gouranton, E.; El Yazidi, C.; Malezet, C.; Balaguer, P.; Borel, P.; Amiot, M. J. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology, 2009, 150(12), 5318-5325.
45. Phillips, S. A.; Ciaraldi, T. P.; Kong, A. P.; Bandukwala, R.; Aroda, V.; Carter, L.; Baxi, S.; Mudaliar, S. R.; Henry, R. R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes, 2003, 52(3), 667-674.
46. Sofer, E.; Boaz, M.; Matas, Z.; Mashavi, M.; Shargorodsky, M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism, 2011, 60(9), 1278-1284.
47. Watanabe, T.; Kubota, N.; Ohsugi, M.; Kubota, T.; Takamoto, I.; Iwabu, M.; Awazawa, M.; Katsuyama, H.; Hasegawa, C.; Tokuyama, K.; Moroi, M.; Sugi, K.; Yamauchi, T.; Noda, T.; Nagai, R.; Terauchi, Y.; Tobe, K.; Ueki, K.; Kadowaki, T. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J. Biol. Chem., 2009, 284(3), 1803-1812.
48. Kaser, S.; Moschen, A.; Cayon, A.; Kaser, A.; Crespo, J.; Pons-Romero, F.; Ebenbichler, C. F.; Patsch, J. R.; Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut, 2005, 54(1), 117-121.
49. Larter, C. Z.; Yeh, M. M.; Williams, J.; Bell-Anderson, K. S.; Farrell, G. C. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J. Hepatol., 2008, 49(3), 407-416.
50. Liu, S.; Wu, H. J.; Zhang, Z. Q.; Chen, Q.; Liu, B.; Wu, J. P.; Zhu, L. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur. J. Pharmacol., 2011, 650(1), 384-389.
51. Shen, Z.; Liang, X.; Rogers, C. Q.; Rideout, D.; You, M. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298(3), G364-374.
52. Tomita, K.; Oike, Y.; Teratani, T.; Taguchi, T.; Noguchi, M.; Suzuki, T.; Mizutani, A.; Yokoyama, H.; Irie, R.; Sumimoto, H.; Takayanagi, A.; Miyashita, K.; Akao, M.; Tabata, M.; Tamiya, G.; Ohkura, T.; Hibi, T. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology, 2008, 48(2), 458-473.
53. Jonsson, J. R.; Moschen, A. R.; Hickman, I. J.; Richardson, M. M.; Kaser, S.; Clouston, A. D.; Powell, E. E.; Tilg, H. Adiponectin and its receptors in patients with chronic hepatitis C. J. Hepatol., 2005, 43(6), 929-936.
54. Corbetta, S.; Redaelli, A.; Pozzi, M.; Bovo, G.; Ratti, L.; Redaelli, E.; Pellegrini, C.; Beck-Peccoz, P.; Spada, A. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur. J. Clin. Invest., 2011, 41(8), 898-905.
55. Lo Iacono, O.; Venezia, G.; Petta, S.; Mineo, C.; De Lisi, S.; Di Marco, V.; Rodolico, V.; Amato, M.; Ferraro, D.; Giordano, C.; Almasio, P. L.; Craxi, A. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther., 2007, 25(10), 1181-1191.
56. Zografos, T. A.; Liaskos, C.; Rigopoulou, E. I.; Togousidis, E.; Makaritsis, K.; Germenis, A.; Dalekos, G. N. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am. J. Gastroenterol., 2008, 103(3), 605-614.
57. Cua, I. H.; Hui, J. M.; Bandara, P.; Kench, J. G.; Farrell, G. C.; McCaughan, G. W.; George, J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 2007, 46(1), 66-73.
58. Palmer, C.; Hampartzoumian, T.; Lloyd, A.; Zekry, A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology, 2008, 48(2), 374-384.
59. Wedemeyer, I.; Bechmann, L. P.; Odenthal, M.; Jochum, C.; Marquitan, G.; Drebber, U.; Gerken, G.; Gieseler, R. K.; Dienes, H. P.; Canbay, A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J. Hepatol., 2009, 50(1), 140-149.
60. Hui, C. K.; Zhang, H. Y.; Lee, N. P.; Chan, W.; Yueng, Y. H.; Leung, K. W.; Lu, L.; Leung, N.; Lo, C. M.; Fan, S. T.; Luk, J. M.; Xu, A.; Lam, K. S.; Kwong, Y. L.; Lau, G. K. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J. Hepatol., 2007, 47(2), 191-202.
61. Liu, C. J.; Chen, P. J.; Lai, M. Y.; Liu, C. H.; Chen, C. L.; Kao, J. H.; Chen, D. S. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol. Int., 2009, 3(2), 364-370.
62. Wong, V. W.; Wong, G. L.; Yu, J.; Choi, P. C.; Chan, A. W.; Chan, H. Y.; Chu, E. S.; Cheng, A. S.; Chim, A. M.; Chan, F. K.; Sung, J. J.; Chan, H. L. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am.J.Gastroenterol., 2010, 105(1), 132-138.
63. Floreani, A.; Variola, A.; Niro, G.; Premoli, A.; Baldo, V.; Gambino, R.; Musso, G.; Cassader, M.; Bo, S.; Ferrara, F.; Caroli, D.; Rizzotto, E. R.; Durazzo, M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol., 2008, 103(8), 1959-1965.
64. Durazzo, M.; Niro, G.; Premoli, A.; Morello, E.; Rizzotto, E. R.; Gambino, R.; Bo, S.; Musso, G.; Cassader, M.; Pagano, G.; Floreani, A. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? J. Gastroenterol., 2009, 44(5), 476-482.
65. Tietge, U. J.; Boker, K. H.; Manns, M. P.; Bahr, M. J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am. J. Physiol. Endocrinol. Metab., 2004, 287(1), E82-E89.
66. Kaser, S.; Moschen, A.; Kaser, A.; Ludwiczek, O.; Ebenbichler, C. F.; Vogel, W.; Jaschke, W.; Patsch, J. R.; Tilg, H. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J. Intern. Med., 2005, 258(3), 274-280.
67. Salman, T. A.; Allam, N.; Azab, G. I.; Shaarawy, A. A.; Hassouna, M. M.; El-Haddad, O. M. Study of adiponectin in chronic liver disease and cholestasis. Hepatol. Int., 2010, 4(4), 767-774.
68. Balmer, M. L.; Joneli, J.; Schoepfer, A.; Stickel, F.; Thormann, W.; Dufour, J. F. Significance of serum adiponectin levels in patients with chronic liver disease. Clin. Sci., 2010, 119(10), 431-436.
69. Lee, Y. J.; Cho, S.; Kim, S. R. The association between serum adiponectin levels and nutritional status of hemodialysis patients. Ren. Fail., 2011, 33(5), 506-511.
70. Stenvinkel, P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J. Ren. Nutr., 2011, 21(1), 82-86.
71. Xu, A.; Wang, Y.; Keshaw, H.; Xu, L. Y.; Lam, K. S.; Cooper, G. J. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest, 2003, 112(1), 91-100.
72. Kamada, Y.; Tamura, S.; Kiso, S.; Matsumoto, H.; Saji, Y.; Yoshida, Y.; Fukui, K.; Maeda, N.; Nishizawa, H.; Nagaretani, H.; Okamoto, Y.; Kihara, S.; Miyagawa, J.; Shinomura, Y.; Funahashi, T.; Matsuzawa, Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology, 2003, 125(6), 1796-1807.
73. Masaki, T.; Chiba, S.; Tatsukawa, H.; Yasuda, T.; Noguchi, H.; Seike, M.; Yoshimatsu, H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology, 2004, 40(1), 177-184.
74. Sennello, J. A.; Fayad, R.; Morris, A. M.; Eckel, R. H.; Asilmaz, E.; Montez, J.; Friedman, J. M.; Dinarello, C. A.; Fantuzzi, G. Regulation of T cellmediated hepatic inflammation by adiponectin and leptin. Endocrinology, 2005, 146(5), 2157-2164.
75. Adachi, M.; Brenner, D. A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology, 2008, 47(2), 677-685.
76. Shafiei, M. S.; Shetty, S.; Scherer, P. E.; Rockey, D. C. Adiponectin regulation of stellate cell activation via PPARgamma-dependent and - independent mechanisms. Am. J. Pathol., 2011, 178(6), 2690-2699.
77. Asano, T.; Watanabe, K.; Kubota, N.; Gunji, T.; Omata, M.; Kadowaki, T.; Ohnishi, S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J. Gastroenterol. Hepatol., 2009, 24(10), 1669-1676.
78. Shu, R. Z.; Zhang, F.; Wang, F.; Feng, D. C.; Li, X. H.; Ren, W. H.; Wu, X. L.; Yang, X.; Liao, X. D.; Huang, L.; Wang, Z. G. Adiponectin deficiency impairs liver regeneration through attenuating STAT3 phosphorylation in mice. Lab. Invest., 2009, 89(9), 1043-1052.
79. Arano, T.; Nakagawa, H.; Tateishi, R.; Ikeda, H.; Uchino, K.; Enooku, K.; Goto, E.; Masuzaki, R.; Asaoka, Y.; Kondo, Y.; Goto, T.; Shiina, S.; Omata, M.; Yoshida, H.; Koike, K. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int. J. Cancer, 2010. in press.
80. Nkontchou, G.; Bastard, J. P.; Ziol, M.; Aout, M.; Cosson, E.; Ganne-Carrie, N.; Grando-Lemaire, V.; Roulot, D.; Capeau, J.; Trinchet, J. C.; Vicaut, E.; Beaugrand, M. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J. Hepatol., 2010, 53(5), 827-833.
81. Kamada, Y.; Matsumoto, H.; Tamura, S.; Fukushima, J.; Kiso, S.; Fukui, K.; Igura, T.; Maeda, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Shimomura, I.; Hayashi, N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol., 2007, 47(4), 556-564.
82. Saxena, N. K.; Fu, P. P.; Nagalingam, A.; Wang, J.; Handy, J.; Cohen, C.; Tighiouart, M.; Sharma, D.; Anania, F. A. Adiponectin modulates C-jun Nterminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology, 2010, 139(5), 1762-1773, 1773 e1761-1765.
83. Sharma, D.; Wang, J.; Fu, P. P.; Sharma, S.; Nagalingam, A.; Mells, J.; Handy, J.; Page, A. J.; Cohen, C.; Anania, F. A.; Saxena, N. K. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 2010, 52(5), 1713-1722.
84. Awazawa, M.; Ueki, K.; Inabe, K.; Yamauchi, T.; Kubota, N.; Kaneko, K.; Kobayashi, M.; Iwane, A.; Sasako, T.; Okazaki, Y.; Ohsugi, M.; Takamoto, I.; Yamashita, S.; Asahara, H.; Akira, S.; Kasuga, M.; Kadowaki, T. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab., 2011, 13(4), 401-412.
85. Ellingsgaard, H.; Hauselmann, I.; Schuler, B.; Habib, A. M.; Baggio, L. L.; Meier, D. T.; Eppler, E.; Bouzakri, K.; Wueest, S.; Muller, Y. D.; Hansen, A. M.; Reinecke, M.; Konrad, D.; Gassmann, M.; Reimann, F.; Halban, P. A.; Gromada, J.; Drucker, D. J.; Gribble, F. M.; Ehses, J. A.; Donath, M. Y. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med., 2011, 17(11), 1481-1489.
86. Duval, C.; Thissen, U.; Keshtkar, S.; Accart, B.; Stienstra, R.; Boekschoten, M. V.; Roskams, T.; Kersten, S.; Muller, M. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes, 2010, 59(12), 3181-3191.
87. Ouedraogo, R.; Gong, Y.; Berzins, B.; Wu, X.; Mahadev, K.; Hough, K.; Chan, L.; Goldstein, B. J.; Scalia, R. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J. Clin. Invest., 2007, 117(6), 1718-1726.
88. Wong, W. T.; Tian, X. Y.; Xu, A.; Yu, J.; Lau, C. W.; Hoo, R. L.; Wang, Y.; Lee, V. W.; Lam, K. S.; Vanhoutte, P. M.; Huang, Y. Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice. Cell Metab., 2011, 14(1), 104-115.
89. Denzel, M. S.; Scimia, M. C.; Zumstein, P. M.; Walsh, K.; Ruiz-Lozano, P.; Ranscht, B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J. Clin. Invest., 2010, 120(12), 4342-4352.
90. Iwabu, M.; Yamauchi, T.; Okada-Iwabu, M.; Sato, K.; Nakagawa, T.; Funata, M.; Yamaguchi, M.; Namiki, S.; Nakayama, R.; Tabata, M.; Ogata, H.; Kubota, N.; Takamoto, I.; Hayashi, Y. K.; Yamauchi, N.; Waki, H.; Fukayama, M.; Nishino, I.; Tokuyama, K.; Ueki, K.; Oike, Y.; Ishii, S.; Hirose, K.; Shimizu, T.; Touhara, K.; Kadowaki, T. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature, 2010, 464(7293), 1313-1319.
91. Zhou, M.; Xu, A.; Tam, P. K.; Lam, K. S.; Chan, L.; Hoo, R. L.; Liu, J.; Chow, K. H.; Wang, Y. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology, 2008, 48(4), 1087-1096.
92. Serviddio, G.; Bellanti, F.; Vendemiale, G.; Altomare, E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol., 2011, 5(2), 233-244.
93. Kim, J. Y.; van de Wall, E.; Laplante, M.; Azzara, A.; Trujillo, M. E.; Hofmann, S. M.; Schraw, T.; Durand, J. L.; Li, H.; Li, G.; Jelicks, L. A.; Mehler, M. F.; Hui, D. Y.; Deshaies, Y.; Shulman, G. I.; Schwartz, G. J.; Scherer, P. E. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest., 2007, 117(9), 2621-2637.
94. Luo, N.; Wang, X.; Chung, B. H.; Lee, M. H.; Klein, R. L.; Garvey, W. T.; Fu, Y. Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo. Am. J. Physiol. Endocrinol. Metab., 2011, 301(1), E180-186.
95. Nakayama, H.; Otabe, S.; Yuan, X.; Ueno, T.; Hirota, N.; Fukutani, T.; Wada, N.; Hashinaga, T.; Yamada, K. Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metabolism., 2009, 58(7), 901-908.